AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06223490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryolipolysis
Description: To investigate the Effect of Cryolipolysis On insulin resistance and In adult type 2 female patients.
Study NCT06781060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy Standard Treatment with TENS machine therapy
Description: The control group in which Standard Physiotherapy + TENS therapy will be provided to the participants.
Study NCT05529576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: Omega-3 fatty acids complementation according to the patient's CRP level
Study NCT05529576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: Omega-3 fatty acids complementation according to the patient's CRP level
Study NCT06780124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE63-0302 or placebo
Description: The participants will receive ZE63-0302 or placebo
Study NCT06782243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Statins
Description: Participants will be administered statins based on moderate intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 20 mg and rosuvastatin 10 mg.
Study NCT06782243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Statins
Description: Participants will be administered statins based on high intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 40 mg and rosuvastatin 20 mg.
Study NCT06780137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6070
Description: IV infusion
Study NCT06780137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan (I-DXd)
Description: IV infusion
Study NCT06780488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Visual-Vestibuar Rehabilitation
Description: The Real Visual-Vestibular Rehabilitation protocol will consist of specific exercises aimed at stimulating the visuo-vestibular function within immersive virtual reality environments replicating daily life situations. Patients will perform exercises in two types of contexts. In all exercises, patients will be free to move within a room large enough to complete the tasks. Walking during the exercises can also be performed with assistive devices, to make the context as close as possible to the patient's daily life. During the exercises, patients will be supervised by a physiotherapist specialized in neurological and vestibular rehabilitation.The protocol will last 20 minutes, with 10 minutes dedicated to each exercise.
Study NCT06780488 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Rehabilitation
Description: The Sham Vestibular Rehabilitation protocol will involve the use of the same immersive virtual reality contexts and will aim to achieve the same objectives as the Real Visual-Vestibular Rehabilitation protocol, but without the unexpected stimuli. In both exercises, patients will be free to move within a room large enough to complete the tasks. Walking during the session can also be performed with assistive devices, to make the context as close as possible to the patient's daily life. During the exercises, patients will be supervised by a physiotherapist specialized in neurological and vestibular rehabilitation. The protocol will last 20 minutes, with 10 minutes dedicated to each exercise.
Study NCT06780683 — intervention group
Intervention type: DRUG
Intervention: Upadacitinib
Description: Induction Therapy: The dose of upadacitinib for induction therapy is 45mg once daily for a duration of 8 weeks (for ulcerative colitis) or 12 weeks (for Crohn's disease).~Maintenance Therapy: The dose of upadacitinib for maintenance therapy is 15mg once daily; for patients with refractory, severe, or extensive disease, a maintenance dose of 30mg once daily may be considered.
Study NCT06780345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mechanically ventilated neonates will receive the usual protocol of sepsis and a placebo without vitamin C.
Study NCT06780345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Mechanically ventilated neonates will receive the usual protocol of sepsis plus vitamin C with a loading dose of 0.5 gm /kg and a maintenance dose of 0.5 gm /kg/hour adjusted for six hours for 7-10 days.
Study NCT04535414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio (Registered trademark) Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes
Description: Participants of both study arms will undergo confocal endomicroscopy of the gastric mucosa until sufficient data for statistically accurate and reliable application of machine learning (i.e., computer models), currently believed to total the first 50 enrolled participants.
Study NCT04535414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellvizio (Registered trademark) Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes
Description: Participants of both study arms will undergo confocal endomicroscopy of the gastric mucosa until sufficient data for statistically accurate and reliable application of machine learning (i.e., computer models), currently believed to total the first 50 enrolled participants.
Study NCT04535414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Graphics Interchange Format (GIF) 190 endoscope
Description: Participants will undergo white light endoscopy. The mucosa of the stomach may be thoroughly washed before examination, as medically indicated, and inspection will include repeated inflation and deflation to check distensibility and any abnormal appearing areas will additionally be biopsied. Nontargeted biopsies will be obtained as indicated per the assigned Arm.
Study NCT04535414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Olympus Graphics Interchange Format (GIF) 190 endoscope
Description: Participants will undergo white light endoscopy. The mucosa of the stomach may be thoroughly washed before examination, as medically indicated, and inspection will include repeated inflation and deflation to check distensibility and any abnormal appearing areas will additionally be biopsied. Nontargeted biopsies will be obtained as indicated per the assigned Arm.
Study NCT04535414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric mucosal biopsy
Description: As clinically indicated.
Study NCT04535414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric mucosal biopsy
Description: As clinically indicated.
Study NCT05929846 — intervention group
Intervention type: OTHER
Intervention: Back to Living Well Program
Description: The Back to Living Well program (BLW), a sustainable community-based program for persons with persistent mild to moderate LBP. The goal of the intervention is to provide an opportunity for community dwelling persons with persistent mild to moderate LBP to learn how to safely engage in exercise and become active self-managers. The 12-week program will engage participants in weekly exercise sessions, education and self management sessions, and encourage independent exercise at least 1x per week. All participants will be encouraged to complete an action plan and watch online education videos weekly.
Study NCT06398457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darzalex Faspro (Daratumumab and hyaluronidase-fihj)
Description: Darzalex Faspro will be administered weekly as a subcutaneous injection on Days -42, -35, -28 and -21 (+/- 1 day) for a total of four doses at 1800 mg each.
Study NCT06398457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JH-DSA Semi-Quant Screen and Response Score
Description: Serum based semi-quantifiable investigational testing regimen used to screen for high DSA level or assess response to desensitization. It is based on results from cross-matched flow cytometric assessment cellular-based and solid phase immunoassays (SPI) that estimates antibody level.
Study NCT04834362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analog Insulin
Description: For a patient who is known to have diabetes but were not getting insulin previously (or previous insulin dosage is not known), insulin therapy will be started at a total daily dose of 0.3-0.4 units/kg/day for an admission BG between 10-15 mmol/L or 0.5-0.6 units/kg/day for a BG >15 mmol/L. In previously insulin treated patients, ongoing total daily dose of insulin will be started. If there is history of poor glycemic control with ongoing insulin dose, then 10-20% increase of daily dose of insulin will be considered.~For a patient who is not known to have diabetes, insulin therapy will be started if admission BG is >10 mmol/L in two or more occasions. A total daily dose of 0.3-0.4 units/kg/day will be started if admission BG is 10-15 mmol/L and 0.5-0.6 units/kg/day for a BG >15 mmol/L.
Study NCT04834362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin
Description: Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm.
Study NCT05733923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Escavation
Description: Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling.~- Group 6: 15 carious teeth will be excavated chemo-mechanically using Selecti-solve.
Study NCT05733923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excavation with Sodium Hypochlorite Gel 2.5%.
Description: Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using Sodium Hypochlorite Gel 2.5%.
Study NCT05733923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excavation with Papacarie Duo
Description: Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Papacarie Duo.
Study NCT05733923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excavation with Brix3000
Description: Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Brix3000.
Study NCT05733923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excavation with Selecti-solve
Description: Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Selecti-solve.
Study NCT04846205 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: systematic etiological
Description: Theses following tests are made as usual practice :~* Ventilator polygraphy, or polysomnography between 1 month and 1 year after cryptogenic ischemic stroke.~* Transoesophageal ultrasound
Study NCT04607915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for TECC Model
Description: The Care Coordinator (CC) will provide brief coaching sessions (15 to 20 minutes) to each participant once per week for 8 weeks. Participants can identify topics for discussion and the CC and participant can decide if a video session via WebEx is required versus a phone call. Also, participants will be given peer support and will be indirectly monitored by a virtual care team of experts.
Study NCT04569708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory stimulation
Description: Quiet auditory stimulation timed with sleep physiology
Study NCT06345209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated Coronary Balloon Dilatation Catheter
Description: During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Sirolimus-coated Coronary Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
Study NCT06345209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-coated Coronary Balloon Dilatation Catheter
Description: During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Drug-coated Coronary Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
Study NCT04917380 — intervention group
Intervention type: OTHER
Description: Retrospective clinical study，no intervention
Study NCT06171880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JC-001(active comparator)
Description: administration of JC-001(tenofovir)
Study NCT06314191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: blood sampling with analyses
Study NCT06314191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling
Description: blood sampling with analyses
Study NCT06314191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knee radiography
Description: radiography of both knees in Schuss
Study NCT06314191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: knee radiography
Description: radiography of both knees in Schuss
Study NCT05290103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game intervention
Description: Game intervention consists of 15-30 minutes digital health game playing at school and 2 weeks free usage of the digital health game during free time. In addition, after the 2 weeks period of game playing, 30-minute debriefing sessions with a research are held.~The digital health game includes visualized elements with sound effects that aim at increasing understanding about the consequences of tobacco product use and supporting refusal skills. The health game includes different mini-games and also textual information.~The debriefing sessions with a researcher include small group and group discussions about the themes presented in the game. A researcher leads and teachers facilitate the discussions. The debriefing sessions aim to connect the game experience with daily life situations.
Study NCT05616182 — intervention group
Intervention type: OTHER
Intervention: LARS ligament and bone prosthesis replacement was performed
Description: To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.
Study NCT05132738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib treatment
Description: Ripretinib: 4-week (28-day) cycle of oral administration of 150 mg q.d. For patients who completed up to 6 consecutive treatment cycles in a the clinical investigator decided whether to perform the operation or not, the specific time and other matters.~The above medications can be adjusted according to the adverse reactions of subjects according to the protocol at the investigator's discretion. Subjects will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or discontinuation of treatment as judged by the investigator, and the investigator will decide whether to perform early surgery or subsequent treatment regimen.
Study NCT05468086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR Solace
Description: Participants will use the VR audio and visual head-mounted device. The device is a standalone VR headset. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
Study NCT06513793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Roots and Shoots
Description: Four-week intervention involving a self-help guidebook to improve mental wellbeing.
Study NCT06513793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Description: Four-week waiting list period involving treatment as usual.
Study NCT04893590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue self-management SMS intervention
Description: Participants will set up an initial goal for the SMS intervention related to fatigue management, and prior to beginning the intervention they will be trained to use the SMS system. Participants will receive text messages each day, providing tips and techniques to help self-manage fatigue. Weekly the participants will be asked to provide feedback regarding their fatigue levels and their patient activation will be re-assessed at the halfway point of intervention.
Study NCT04080115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training Technique
Description: ATT will be administered through a customized Expiwell smartphone application that will be downloaded onto participants' cell phones at the first laboratory session (T2). For the purposes of the proposed study, participants need to complete the intervention once a day, for the six days between their lab sessions; signals will begin the day after their T2 session and they will be notified up to a maximum of five times per day to complete their daily session. The ATT sessions are comprised of three phases. The first is a 5-minute phase during which the participant is instructed to attend to specific sounds in the recording and disregard other sounds. The subsequent 5-minute phase includes instructions to rapidly switch their attention between sounds in the recording. The final phase is a dual attention task lasting 2 minutes wherein the participant is instructed to pay attention to multiple sounds in the recording at once. In total, each session of ATT lasts 12 minutes.
Study NCT04080115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham intervention control condition
Description: The sham control condition consists of the same 12 minutes of simultaneous sounds as the ATT technique, but will not include any verbal instruction, thus isolating the effects of intentional orientation of attention.
Study NCT05170139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Participants will ingest a drink with 3mg/kg of body weight mixed with carbohydrates
Study NCT05170139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Participants will ingest the exact same drink without caffeine
Study NCT04848363 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus lumborum block
Description: QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.
Study NCT04848363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.
Study NCT05827146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide
Description: Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
Study NCT06168656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: The mobile application will include the following features:~Direct Message Section: This section will allow expectant fathers to ask specialized questions directly to experts or specialists.~Forum Section: Expectant fathers can use this section to engage in discussions and connect with each other.~Education Section: This section is specifically designed to cater to the educational needs of expectant fathers.
Study NCT05827146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hepalatide Placebo
Description: Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
Study NCT05207436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each B-CBCT session.
Study NCT05207436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive-Behavioral Conjoint Therapy
Description: Eight sessions of standardized B-CBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
Study NCT05762939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Participants in this condition were asked to use Fido, a Polish therapy chatbot, for two weeks. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
Study NCT05762939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (book)
Description: Participants in this condition were told to read selected chapters from a self-help book during the two-week intervention period. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
Study NCT05218122 — intervention group
Intervention type: OTHER
Intervention: cross-sectional study without intervention
Description: cross-sectional study without intervention
Study NCT05313009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib and Tarloxotinib
Description: Sotorasib 960 mg PO daily + tarloxotinib 150 mg/m2 IV weekly
Study NCT05313009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib and Tarloxotinib
Description: Sotorasib 960 mg PO daily + tarloxotinib IV weekly at the combination RP2D (RP2Dc).
Study NCT05440799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479
Study NCT05440799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI matching placebo
Description: BI matching placebo